Bio-View Ltd
Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company's products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatic… Read more
Bio-View Ltd (BIOV) - Net Assets
Latest net assets as of June 2025: ILA19.93 Million ILA
Based on the latest financial reports, Bio-View Ltd (BIOV) has net assets worth ILA19.93 Million ILA as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA28.19 Million) and total liabilities (ILA8.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA19.93 Million |
| % of Total Assets | 70.71% |
| Annual Growth Rate | 19.69% |
| 5-Year Change | -8.47% |
| 10-Year Change | -0.18% |
| Growth Volatility | 106.95 |
Bio-View Ltd - Net Assets Trend (2009–2024)
This chart illustrates how Bio-View Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bio-View Ltd (2009–2024)
The table below shows the annual net assets of Bio-View Ltd from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ILA22.95 Million | -15.96% |
| 2023-12-31 | ILA27.30 Million | -3.43% |
| 2022-12-31 | ILA28.28 Million | +4.11% |
| 2021-12-31 | ILA27.16 Million | +8.34% |
| 2020-12-31 | ILA25.07 Million | +0.48% |
| 2019-12-31 | ILA24.95 Million | +9.68% |
| 2018-12-31 | ILA22.75 Million | -3.01% |
| 2017-12-31 | ILA23.45 Million | -15.03% |
| 2016-12-31 | ILA27.61 Million | +20.08% |
| 2015-12-31 | ILA22.99 Million | +26.43% |
| 2014-12-31 | ILA18.18 Million | +16.19% |
| 2013-12-31 | ILA15.65 Million | -6.26% |
| 2012-12-31 | ILA16.69 Million | +9.84% |
| 2011-12-31 | ILA15.20 Million | +85.89% |
| 2010-12-31 | ILA8.18 Million | +428.17% |
| 2009-12-31 | ILA1.55 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bio-View Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2695800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ILA49.90 Million | 217.48% |
| Total Equity | ILA22.95 Million | 100.00% |
Bio-View Ltd Competitors by Market Cap
The table below lists competitors of Bio-View Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
QV KOSPI Vol Matching Strangle
KO:550057
|
$54.72K |
|
MANITEX INTL
BE:VE8
|
$54.73K |
|
RENTOKIL INITIAL
MU:RTO1
|
$54.75K |
|
CHINA MERCHANT -H-
MU:M4B
|
$54.78K |
|
Mount Logan Capital Inc. Common Stock
NASDAQ:MLCI
|
$54.59K |
|
YANGTZE OPTICAL FIBRE AND
BE:1YO
|
$54.59K |
|
East Delta Flour Mills
EGX:EDFM
|
$54.56K |
|
GEPA3F
SA:GEPA3F
|
$54.56K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bio-View Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 27,305,000 to 22,946,000, a change of -4,359,000 (-16.0%).
- Net loss of 3,148,000 reduced equity.
- Share repurchases of 1,400,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-3.15 Million | -13.72% |
| Share Repurchases | ILA1.40 Million | -6.1% |
| Other Changes | ILA189.00K | +0.82% |
| Total Change | ILA- | -15.96% |
Book Value vs Market Value Analysis
This analysis compares Bio-View Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 95.37x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 10.06x to 95.37x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ILA1.68 | ILA16.90 | x |
| 2018-12-31 | ILA1.63 | ILA16.90 | x |
| 2019-12-31 | ILA1.75 | ILA16.90 | x |
| 2020-12-31 | ILA1.83 | ILA16.90 | x |
| 2021-12-31 | ILA1.98 | ILA16.90 | x |
| 2022-12-31 | ILA2.07 | ILA16.90 | x |
| 2023-12-31 | ILA0.20 | ILA16.90 | x |
| 2024-12-31 | ILA0.18 | ILA16.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bio-View Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -13.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -12.27%
- • Asset Turnover: 0.76x
- • Equity Multiplier: 1.47x
- Recent ROE (-13.72%) is below the historical average (14.03%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 72.16% | 4.96% | 1.53x | 9.48x | ILA962.20K |
| 2010 | 64.04% | 20.68% | 1.18x | 2.62x | ILA4.42 Million |
| 2011 | 43.27% | 25.13% | 0.89x | 1.94x | ILA5.06 Million |
| 2012 | 8.64% | 5.54% | 0.87x | 1.79x | ILA-227.40K |
| 2013 | -6.88% | -4.67% | 0.83x | 1.78x | ILA-2.64 Million |
| 2014 | 11.59% | 6.97% | 0.97x | 1.71x | ILA289.80K |
| 2015 | 17.69% | 11.77% | 1.03x | 1.45x | ILA1.77 Million |
| 2016 | 16.07% | 13.33% | 0.86x | 1.40x | ILA1.68 Million |
| 2017 | -5.34% | -4.51% | 0.80x | 1.48x | ILA-3.60 Million |
| 2018 | -8.15% | -7.33% | 0.76x | 1.47x | ILA-4.13 Million |
| 2019 | 10.12% | 7.06% | 0.97x | 1.48x | ILA30.00K |
| 2020 | 3.53% | 3.41% | 0.77x | 1.35x | ILA-1.62 Million |
| 2021 | 8.04% | 7.16% | 0.76x | 1.47x | ILA-532.00K |
| 2022 | 2.08% | 2.01% | 0.70x | 1.48x | ILA-2.24 Million |
| 2023 | 1.40% | 1.10% | 0.83x | 1.54x | ILA-2.35 Million |
| 2024 | -13.72% | -12.27% | 0.76x | 1.47x | ILA-5.44 Million |
Industry Comparison
This section compares Bio-View Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $48,148,556
- Average return on equity (ROE) among peers: -5.43%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bio-View Ltd (BIOV) | ILA19.93 Million | 72.16% | 0.41x | $54.59K |
| Allmed Solutions Ltd (ALMD) | $45.13 Million | -46.38% | 0.26x | $96.61K |
| Erika Carmel Ltd (BCUR) | $8.97 Million | 138.94% | 4.32x | $46.92K |
| Erech Finance Cahalacha Ltd (EFNC) | $-63.00K | 0.00% | 0.00x | $19.28K |
| Endymed (ENDY) | $14.70 Million | 5.78% | 0.34x | $118.10K |
| Epitomee Medical Ltd (EPIT) | $34.80 Million | -16.33% | 0.16x | $567.43K |
| Human Xtensions Ltd (HUMX) | $61.78 Million | -72.18% | 0.17x | $21.16K |
| Ilex Medical (ILX) | $109.44 Million | 17.00% | 0.55x | $2.01 Million |
| Pulsenmore Ltd (PULS) | $132.23 Million | -44.29% | 0.36x | $321.83K |
| Sofwave Medical Ltd (SOFW) | $26.34 Million | -31.42% | 0.65x | $3.18 Million |